Compounders Research Compare

CeriBell, Inc.(CBLL)

Medical - Devices · Sunnyvale, CA

$24.53-0.33 (-1.33%)

Delayed quote: Oct 6, 2026, 1:04 PM EDT

About CeriBell, Inc.

CeriBell, Inc. specializes in pioneering artificial intelligence (AI)-powered electroencephalography (EEG) solutions designed for the immediate diagnosis and treatment of neurological conditions directly at the patient's bedside. The company's primary offering is the Ceribell System, an innovative, on-site EEG platform engineered to fulfill crucial, previously unmet requirements for patients in urgent medical environments. Beyond the core system, CeriBell also provides single-use EEG headbands and compact, battery-powered recording devices. Originally established in 2014 as Brain Stethoscope, Inc., the company underwent a name change to CeriBell, Inc. in August 2015. Its headquarters are located in Sunnyvale, California.

Sunnyvale, CA

327 employees

Healthcare / Medical - Devices

Sector: Healthcare
Industry: Medical - Devices
CEO: Xingjuan Chao

View full financials

EV/FCF Ratio: N/A

Basis: Current FMP quote-based enterprise value / four-quarter operating cash flow less absolute capital expenditures. Source: stored company filings and market data; unavailable inputs remain N/A.

The EV/FCF ratio is N/A as of 2026-10-06T17:06:06.691Z.

Stored calculation inputs

Calculation as of: 2026-10-06T17:06:06.691Z.

Quote observation: 2026-10-06T17:04:55.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 930,734,431
Total debt · period ending 2026-06-30: 21,909,000
Cash · period ending 2026-06-30: 32,663,000
TTM free cash flow · period ending 2026-06-30: -56,331,000

FMP input reference: cf0630fc9642b75147419b140bafddb7ccff0a2362c2d95f2dd7172ee2000ae5

Free Cash Flow|FCF Yield|P/FCF Ratio|EV/EBITDA|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

CBLL EV/FCF Ratio Metrics

EV/FCF RATIO

N/A

CBLL Competitors' EV/FCF Ratio

CeriBell, Inc.

Current

Market Cap

$930.73M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MoonLake Immunotherapeutics

Market Cap

$939.15M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Odyssey Therapeutics, Inc.

Market Cap

$917.90M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HealthStream, Inc.

Market Cap

$914.89M

EV/FCF Ratio

18.06x

TTM Avg

12.91x

3Y Avg

14.88x

5Y Avg

16.28x

Seaport Therapeutics, Inc. Common Stock

Market Cap

$948.56M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Kura Oncology, Inc.

Market Cap

$949.44M

EV/FCF Ratio

N/A

TTM Avg

6.09x

3Y Avg

6.07x

5Y Avg

6.07x

Savara Inc.

Market Cap

$953.94M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Bioventus Inc.

Market Cap

$897.61M

EV/FCF Ratio

12.00x

TTM Avg

13.69x

3Y Avg

60.52x

5Y Avg

99.98x

Aktis Oncology, Inc.

Market Cap

$968.36M

EV/FCF Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

Arbutus Biopharma Corp

Market Cap

$887.93M

EV/FCF Ratio

N/A

TTM Avg

14.36x

3Y Avg

10.42x

5Y Avg

10.42x

NAME	MARKET CAP	EV/FCF RATIO	TTM	3Y	5Y
CeriBell, Inc. (CBLL)	$930.73M	N/A	N/A	N/A	N/A
MoonLake Immunotherapeutics (MLTX)vs ›	$939.15M	N/A	N/A	N/A	N/A
Odyssey Therapeutics, Inc. (ODTX)vs ›	$917.90M	N/A	N/A	N/A	N/A
HealthStream, Inc. (HSTM)vs ›	$914.89M	18.06x	12.91x	14.88x	16.28x
Seaport Therapeutics, Inc. Common Stock (SPTX)vs ›	$948.56M	N/A	N/A	N/A	N/A
Kura Oncology, Inc. (KURA)vs ›	$949.44M	N/A	6.09x	6.07x	6.07x
Savara Inc. (SVRA)vs ›	$953.94M	N/A	N/A	N/A	N/A
Bioventus Inc. (BVS)vs ›	$897.61M	12.00x	13.69x	60.52x	99.98x
Aktis Oncology, Inc. (AKTS)vs ›	$968.36M	N/A	N/A	N/A	N/A
Arbutus Biopharma Corp (ABUS)vs ›	$887.93M	N/A	14.36x	10.42x	10.42x

Cash Flow Valuation Comparison

EV/FCF

N/A

P/FCF

N/A

FCF Yield

N/A

Formula: EV/FCF = Enterprise Value / Free Cash Flow

EV/FCF vs P/FCF:

EV/FCF accounts for debt and cash through enterprise value
P/FCF only considers equity value
EV/FCF can be compared across companies with different debt levels
Both measure how the market values cash generation

EV/FCF Ratio Formula & Definition

EV/FCF = Enterprise Value / Free Cash Flow (TTM)

Enterprise value to free cash flow compares total company value to the cash the business generates after capital expenditures.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Related Metrics

Free Cash Flow FCF Yield P/FCF Ratio EV/EBITDA All Metrics